The beneficial effect of SGLT2 inhibitors on cardiovascular death or worsening HF was independent of the presence of AF in the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trial.21 However, the opposite is not necessarily true, so that SGLT2 inhibitors may not prevent AF regardless of the type of HF. This evidence concerns the gene SLC5A2 and hydrops fetalis.